High growth hormone serum partially protects mice against Trypanosoma cruzi infection
FEBS Open Bio · 2023
DOI: 10.1002/2211-5463.13627 ↗Kurz gefasst
Fachartikel in der Zeitschrift FEBS Open Bio, 2023. Verfasst von Patricia Mora-Criollo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Infectious and Tropical Disease Institute, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH, …. Hauptthemen laut MEDLINE: Insulin-Like Growth Factor I, Chagas Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chagas disease (CD) is one of the most devasting parasitic diseases in the Americas, affecting 7–8 million people worldwide. In vitro and in vivo experiments have demonstrated that growth hormone (GH) serum levels decrease as CD progresses. Interestingly, inactivating mutations in the GH receptor in humans result in Laron syndrome (LS), a clinical entity characterized by increased serum levels of GH and decreased insulin growth factor‐1 (IGF‐1). The largest cohort of LS subjects lives in the southern provinces of Ecuador. Remarkably, no clinical CD cases have been reported in these individuals despite living in highly endemic areas. In the current ex vivo study, we employed serum from GHR −/− mice, also known as LS mice (a model of GH resistance with high GH and low IGF‐1 levels), and serum from bovine GH (bGH) transgenic mice (high GH and IGF‐1), to test the effect on Trypanosoma cruzi infection. We infected mouse fibroblast L‐cells with T. cruzi (etiological CD infectious agent) and treated them with serum from each mouse type. Treatment with GHR −/− serum (LS mice) significantly decreased L‐cell infection by 28% compared with 48% from control wild‐type mouse serum (WT). Treatment with bGH mouse serum significantly decreased infection of cells by 41% compared with 54% from WT controls. Our results suggest that high GH and low IGF‐1 in blood circulation, as typically seen in LS individuals, confer partial protection against T. cruzi infection. This study is the first to report decreased T. cruzi infection using serum collected from two modified mouse lines with altered GH action (GHR −/− and bGH).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Infectious and Tropical Disease Institute, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH, USA.
- Edison Biotechnology Institute, Ohio University, Athens, OH, USA.
- Heritage College of Osteopathic Medicine, Ohio University, Athens, OH, USA.
- Centro de Investigación para la Salud en América Latina, Escuela de Ciencias Biológicas, Facultad de Ciencias Exactas y Naturales, Pontificia Universidad Católica del Ecuador, Quito, Ecuador.
- Colegio de Ciencias de la Salud, Universidad San Francisco de Quito, Ecuador.
- Faculty of Health Medicine and Life Sciences, Maastricht University, The Netherlands.
ORCID-Profile: Patricia Mora-Criollo, Reetobrata Basu, Jonathan A Young, Mario J Grijalva, John J Kopchick
Zitieren
APA
Mora-Criollo, P., Basu, R., Qian, Y., Funk, K., Bell, S., Young, J. A., List, E. O., Costales, J. A., Guevara-Aguirre, J., Grijalva, M. J., & Kopchick, J. J. (2023). High growth hormone serum partially protects mice against Trypanosoma cruzi infection. FEBS Open Bio. https://doi.org/10.1002/2211-5463.13627
Vancouver
Mora-Criollo P, Basu R, Qian Y, Funk K, Bell S, Young JA, et al. High growth hormone serum partially protects mice against Trypanosoma cruzi infection. FEBS Open Bio. 2023. doi:10.1002/2211-5463.13627
BibTeX
@article{MoraCriollo2023,
author = {Mora-Criollo, Patricia and Basu, Reetobrata and Qian, Yanrong and Funk, Kevin and Bell, Stephen and Young, Jonathan A and List, Edward O and Costales, Jaime A and Guevara-Aguirre, Jaime and Grijalva, Mario J and Kopchick, John J},
title = {High growth hormone serum partially protects mice against Trypanosoma cruzi infection},
journal = {FEBS Open Bio},
year = {2023},
doi = {10.1002/2211-5463.13627}
}
EUVIMED